Recent advances in cellular therapy for malignant lymphoma |
| |
| Institution: | 1. Elite Regenerative Stem Cell Specialists, LLC, Johnstown, Colorado, USA;2. R&D Regenerative Laboratory Resources, LLC, Johnstown, Colorado, USA;3. Colorado Spine Institute, PLLC, Johnstown, Colorado, USA;1. Department of Regenerative Technologies and Biofabrication, National Medical Research Radiological Center, Obninsk, Russia;2. Basel University, Basel, Switzerland;1. Liver Group, Institute for Liver and Digestive Health, Royal Free Campus, University College London, London, UK;2. Department of Biochemical Engineering, Advanced Centre for Biochemical Engineering, University College London, London, UK;1. Department of Surgery, Division of Plastic Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA;2. Department of Plastic and Cosmetic Surgery, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China;3. MTF Biologics, Edison, New Jersey, USA;1. Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri, USA;2. Department of Laboratories, Barnes-Jewish Hospital, St Louis, Missouri, USA |
| |
| Abstract: | Cellular therapies for malignant lymphoma include autologous or allogeneic hematopoietic stem cell transplantation (HSCT) and adaptive cellular therapy using EBV-specific T cells, cytokine-induced killer (CIK) cells, NKT cells, NK cells, chimeric antigen receptor T (CAR-T) cells and chimeric antigen receptor NK (CAR-NK) cells. In this review we discusses recent advances of these cellular therapies and consider ways to optimize these therapies. Not only a single strategy using one of these cellular therapies, but also multi-disciplinary treatment combines with antibodies, such as an anti-tumor antibody and an immune checkpoint antibody, may be more effective for relapsed and refractory lymphoma. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
